

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmt.org/>

Original Research Article

Candidemia in a tertiary care hospital: Changing trends

Devashree Kshirsagar¹, Vrushali Harsh Thakar¹, Bharati Avinash Dalal¹,
Aishwarya Babu^{1*}, Meera Modak¹, Mahadevan Kumar¹

¹Dept. of Microbiology, Bharati Vidyapeeth Deemed University Medical College, Pune, Maharashtra, India



ARTICLE INFO

Article history:

Received 09-07-2024

Accepted 08-08-2024

Available online 27-09-2024

Keywords:

Azoles

C.parapsilosis

Non albicans candida

ABSTRACT

Background: *Candida* has emerged as a major cause of blood stream infections and ranks among the top ten pathogens responsible for hospital acquired infections. It is more common in children and adults admitted in critical care units. Though *Candida albicans* was the most commonly isolated species there has been a shift to Non-albicans species of *Candida* (NAC) as the major causative agent in the recent years. Many NAC are also intrinsically resistant to azoles.

Materials and Methods: Blood samples from patients with suspected candidemia were received in automated blood culture bottles. *Candida* species were identified using standard microbiological techniques, including CHROM agar and VITEK 2 compact. Patient's demographic and clinical details were collected. Data was analyzed using Microsoft excel.

Results: Out of the 4367 blood culture samples received, 131 (2.99%) grew *candida* species. Most frequently isolated species was *Candida parapsilosis* (32%) followed by *C.tropicalis* (29%). Antifungal resistance was notable: 26.8% of isolates were resistant to fluconazole, 11.5% to voriconazole, 10% to caspofungin, 7.7% to micafungin and 18.4% to amphotericin B. Mortality due to candidemia was 16.79%, with *C.parapsilosis* being the most prevalent species among deceased patients

Conclusions: With the emergence of drug-resistant *Candida* species, the treatment of candidemia is becoming increasingly challenging. Rapid diagnosis, early treatment, adherence to proper infection control and antimicrobial stewardship practices are essential to reduce the burden of candidemia in developing countries like India. Effective management strategies are crucial to improve patient outcomes and combat the rising threat of antifungal resistance.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Candida species are normal inhabitants of skin and mucosa.¹ It can become pathogenic in situations where the host defences are disturbed. Risk factors include immunocompromised conditions like diabetes mellitus, prolonged use of steroids, long term use of antibiotics, old age, presence of indwelling devices and recent gastrointestinal surgery.^{1,2} *Candida* can cause various clinical manifestations like oropharyngeal candidiasis,

vulvovaginal candidiasis, genitourinary candidiasis and blood stream infections.³ Over the past two decades, blood stream infections (BSI) caused by *Candida* species are increasing. Prevalence of candidemia in India (2020) ranges from 1.31%- 3.41%.^{4,5} Although *Candida albicans* was considered as the most common species causing candidemia, BSI caused by Non-albicans *Candida*(NAC) species like *C. tropicalis* & *C. parapsilosis* (in developing countries) and *C. glabrata* (in developed nations) are emerging as a major cause of nosocomial infections.^{5,6} Increased morbidity and prolonged hospital stay are

* Corresponding author.

E-mail address: aishwaryabkk@gmail.com (A. Babu).

associated with invasive candidiasis resulting in mortality. Mortality associated with candidemia is estimated to be 19–24% by CDC.⁷

Fluconazole is the most commonly used antifungal for the treatment of candidemia. *Candida krusei* is intrinsically resistant to fluconazole. Other NAC species like, *Candida guilliermondii*, *C.glabrata* *C. inconspicua* are less susceptible to azoles. Though resistance to echinocandins is considered rare, it is also on the rise. Intrinsic and acquired resistance to various antifungals is becoming a major problem in treatment of candidemia.² Therefore it is important to identify the *Candida* species causing sepsis and determine their antifungal susceptibility pattern to select the right antifungal giving appropriate coverage. This will help in effective management of these patients, thus reducing mortality caused by *Candida* and also to control outbreaks.⁸ This study was undertaken to find out prevalence of *Candida* species causing sepsis and its outcome in a tertiary care hospital.

2. Materials and Methods

2.1. Study design

Descriptive cross-sectional study.

2.2. Study period

July 2021 to June 2023.

2.3. Place of study

Department of Microbiology, tertiary care hospital, Pune

2.4. Methodology

All the blood samples received during the study period and which grew *Candida* species were included in the study. Blood cultures which grew organisms other than *Candida* species were excluded from the study. Blood samples of patients with suspected candidemia were received in automated blood culture bottles (BD BACTECFX 40) and were incubated in the automated BD BACTEC TM FX (Becton, Dickinson and Company, NJ, and USA). Once the bottle flagged positive, Gram stain was done and presence of gram positive budding yeast cells was recorded. Gram's staining findings were immediately communicated to clinician for early start of antifungal therapy. *Candida* species were identified by routine conventional methods like growth on blood agar (Figure 1), SDA (Sabouraud Dextrose Agar), germ tube test, CHROM agar *Candida* (HiMedia, Mumbai, India) (Figure 2) and automated identification system (VITEK 2 compact - BioMérieux, France). In vitro antifungal susceptibility profile was determined by the automated antifungal susceptibility system (VITEK 2 BioMérieux, France). Demographic and clinical details of the patients were collected.

2.5. Statistical analysis

The collected data was entered in Microsoft excel sheet and analysed. Data presented as numbers and percentages.

3. Results

A total of 4367 blood cultures were received during the study period. Of this, 131(2.99%) grew *Candida* species. 36 (out of the 131) isolates were obtained from children below one year of age (Table 1). Majority {91 of 131 (69.4%)} of the patients were admitted in critical care units (ICUs) (Figure 3), out of which (45) 34.35% were adults, while (46)35.1% were children below 10 years. Male and female patients were equally affected. Majority of the patients had associated co-morbidities like diabetes mellitus, malignancy, chronic kidney disease (Table 2). *C. parapsilosis* was isolated from 42 samples (32%), followed by *C. tropicalis* 38 (29%), *C. albicans* 30 (22.9%), *C.guilliermondi* 07 (5.34%), *C.glabrata* 06 (4.58%), *C.krusei* 05 (3.8) and *C.lusitaniae* 01 (0.78) (Figure 4). Antifungal susceptibility pattern of the *Candida* isolates showed that 73.2% were susceptible to fluconazole, 88.5% to voriconazole, 90% to caspofungin, 92.3% to micafungin, 81.6% to amphotericin B and 100% to flucytosine (Figure 5). A total of 16.6% of *C.parapsilosis* strains were resistant to fluconazole, voriconazole and amphotericin B while 7.4% were resistant to caspofungin and micafungin. Seventeen (44.7%) *C.tropicalis* strains were resistant to fluconazole, 7 (18.4%) were resistant to amphotericin B and voriconazole while 4(10.5%) were resistant to caspofungin and micafungin each. *C.albicans* strains were fully susceptible to all antifungal agents except (n=4)13.3% of strains which were resistant to fluconazole (Table 3) Antifungal susceptibility testing of *Candida auris* isolates could not be performed.

3.1. Follow up

Twenty two (16.79%) patients succumbed to candidemia (Table 4). All others responded to azole group of drugs. Two patients infected with *Candida auris* were treated with echinocandins. Contact precautions were followed while handling these patients.

4. Discussion

Over the recent years, *Candida* has emerged as a major cause of blood stream infections. In the United States, *Candida* species have been found to be the fourth most common cause of blood stream infections.⁹ *Candida* ranks among the top ten pathogens responsible for hospital acquired blood stream infections.² A study by Chakrabarti A has found that the rate of candidemia in developing countries is 4-15 times more than in developed countries.¹⁰ The prevalence of candidemia was found to be 2.99 %

Table 1: Age wise distribution of patients

Age group (in years)	Number of patients
0-1	36
1-10	09
11-20	08
21-30	07
31-40	13
41-50	30
51-60	15
61-70	07
71-80	06
>80	0
Total	131

Table 2: Associated Co-morbidities

Co-morbidities associated	Number of patients with risk factors
Diabetes mellitus	40
Chronic kidney disease	20
Malignancy	25
Prolonged use of broad spectrum antibiotic	90
Prolonged stay in ICU/NICU (>1 month)	30
Total parenteral nutrition	20
Premature neonates with respiratory distress	25
Presence of CVC	28

Abbreviations used: NICU- Neonatal ICU, PICU- Paediatric ICU

Table 3: Antifungal resistance in different *Candida* species *100% susceptible to Flucytosine

<i>Candida</i> species	Fluconazole	Voriconazole	Caspofungin	Micafungin	Amphotericin B
<i>C. albicans</i>	4	0	0	0	0
<i>C. parapsilosis</i>	7	7	3	3	7
<i>C. tropicalis</i>	17	7	4	4	7
<i>C. guilliermondii</i>	3	1	2	2	2
<i>C. krusei</i>	5IR	0	0	0	5
<i>C. glabrata</i>	4	0	4	1	3
<i>C. lusitaniae</i>	0	0	0	0	0

Abbreviations used- IR: Intrinsic resistance

Table 4: *Candida* species isolated from patients who expired due to candidemia

<i>Candida</i> species isolated	Number of patients
<i>C. parapsilosis</i>	9
<i>C. tropicalis</i>	7
<i>C. glabrata</i>	4
<i>C. albicans</i>	1
<i>C. guilliermondii</i>	1

in our study. The prevalence of candidemia was found to be 3.4% by Ahmed S et al in Uttar Pradesh, 1.3% by Kaur H et al in Chandigarh (North India), 1.4% by Jain V et al in Rajasthan (Western India), 3.8% by Behera C et al in Bhubaneswar (Eastern India) and 0.65% by Giri S et al in Tamil Nadu (South India).^{4,5,11–13} In our study, 27.4% of the population was below 1 year of age. As per Mantadakis E et al, candidemia is several times more common in infants and neonates than in adults. Main risk factors associated with candidemia in children

were respiratory diseases, prematurity, ICU admission, mechanical ventilation, neutropenia, and malignancy.¹⁴ In our study comorbidities associated with candidemia in neonates were prematurity and respiratory distress syndrome. All the children were admitted in critical care units. In the present study the risk factors in adults were diabetes mellitus, chronic kidney disease and malignancy. In the study of Blyth et al., renal disease, recent surgery, diabetes mellitus and haemodialysis were the frequent risk factors in adults.¹⁵ Underlying conditions




Figure 1: Growth of *Candida* on blood agar

Species of *Candida* isolated




Figure 4: Isolated *Candida* species




Figure 2: CHROM agar

Susceptibility pattern of *Candida* isolates




Figure 5: Antifungal susceptibility pattern of all *Candida* isolates




Figure 3: Location of patients

like renal insufficiency, trauma, gastrointestinal perforation, prolonged use of broad spectrum antibiotics, stay in ICU or use of central venous catheter were predisposing factors in a study done by Capoor MR et al.¹⁶ It has been observed that candidemia is more common in diabetic patients because of the adhesion of yeast to host epithelium, high serum glucose levels as compared to healthy individuals, poor candidacidal activity of neutrophils and microvascular degeneration.¹⁷ In present study, 19.0% (25) had history of malignancy. Presence of central venous catheter or parenteral nutrition were the reason for development of candidemia in patients with hematologic malignancies in a study by Girmenia C et al.¹⁸

In India, a change in trend of species causing candidemia in the recent years from *C. albicans* to NAC⁶ has been observed. Along with *C. albicans*, other NAC species like *C. parapsilosis*, *C. krusei*, *C. tropicalis* and *C. glabrata* contribute to 92% of cases candidemia globally. *Candida glabrata* is common in elderly patients and *Candida albicans* is more common in children upto 18 years of age.¹⁹ *Candida auris* which was considered a rare pathogen

previously is also becoming a prominent pathogen.²⁰ This shift could be due to better detection rate of NAC or as a result of rampant use of fluconazole for treatment of all fungal infections resulting in shift in the colonisation and infection with fluconazole resistant strains like *C. krusei*.^{21–28} In our study, *Candida parapsilosis* was the commonest species (32%) which correlated with the studies undertaken by Shivprakash et al (28.8%) and Capoor et al. (27.4%).^{6,16} Low prevalence of *C. parapsilosis* was reported in studies conducted by Sridharan et al (17%) and Bhattacharje et al (17%) and Amir et al (8%).^{22,27,28}

Fluconazole is the preferred antifungal for treatment of less severe infections while echinocandins are preferred for moderate to severe infections or in systemic candidiasis as per the guidelines from the Infectious Diseases Society of America.² Fluconazole being the most frequently used antifungal, its resistance is on the rise in many parts of the world.⁴ Various studies have reported resistance to fluconazole i.e 10% by Seyoum E et al in Ethiopia(2020),15% by Bilal H et al in China (2022), 5% by Bedini A et al in Italy(2006) and 34.8% by Bhattacharjee P et al in India(2016).^{21–24} In the present study 26.7% of the isolates were resistant to fluconazole. This is slightly higher than other studies as candidemia caused by NAC was more common in this study. Many species of *candida* are intrinsically resistant to many antifungals. *C. auris* is intrinsically resistant to polyenes and fluconazole while *C. krusei* is intrinsically resistant to fluconazole. Empiric antifungal therapy is usually given in febrile neutropenia patients who do not respond to antibiotic therapy and in cases of perforated peritonitis. This has led to the development of acquired resistance to many antifungals especially the azoles. Mechanisms by which azoles develop resistance are over expression of membrane transporters, alteration of ergosterol biosynthesis, sterol import alteration and genome plasticity.²⁵

Hand hygiene, isolation of patient, environmental disinfection and avoiding unnecessary use of broad spectrum antibiotics are measures by which candidemia can be controlled to an extent. If the patient is on central venous catheter, it must be regularly monitored for signs of infection.²⁶

5. Conclusion

The prevalence of candidemia was found to be 2.99%, with an increasing trend of bloodstream infections caused by non-albicans *Candida* (NAC) species. Most cases occurred in patients admitted in critical care units. Commonly isolated species were *Candida parapsilosis* and *Candida tropicalis*, many of which showed resistance to the commonly used antifungal fluconazole. The recent emergence of *Candida auris* has further complicated the treatment of candidemia. Rapid diagnosis, early treatment, strict infection control measures, and robust antimicrobial

stewardship practices are essential to reduce the burden of candidemia.

6. Ethical Approval

This study was approved by the institutional Ethical Committee (Approval number-BVDUMC/IEC/263).

7. Conflict of Interest

None.

8. Source of Funding

None.


References


- Mohandas V, Ballal M. Distribution of *Candida* species in different clinical samples and their virulence: biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in southern India. *J Glob Infect Dis*. 2011;3(1):4–8.
- Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among *Candida* species: mechanisms and clinical impact. *Mycoses*. 2015;58(2):2–13.
- Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis*. 2005;41(9):1232–9.
- Ahmed S, Shahid M, Fatima N, Khan F, Tayyaba U. Candidemia – Changing Trends from *Candida albicans* to Non-*Albicans* *Candida* from a Tertiary Care Center in Western UP, India. *CHRISMED J Health Res*. 2020;7(3):167–72.
- Kaur H, Singh S, Rudramurthy SM, Ghosh AK, Jayashree M, Narayana Y, et al. Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility. *Indian J Med Microbiol*. 2020;38(1):109–16.
- Shivaprakasha S, Radhakrishnan K, Karim PM. *Candida* spp. other than *Candida albicans*: a major cause of fungaemia in a tertiary care centre. *Indian J Med Microbiol*. 2007;25(4):405–7.
- Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. *Infect Control Hospital Epidemiol*. 2005;26(6):540–7.
- Montes K, Ortiz B, Galindo C, Figueroa I, Braham S, Fontecha G, et al. Identification of *Candida* Species from Clinical Samples in a Honduran Tertiary Hospital. *Pathogens*. 2019;8(4):237. doi:10.3390/pathogens8040237.
- Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. *Antimicrob Agents Chemother*. 2005;49(9):3640–5.
- Chakrabarti A. Fungal Infections in Asia: Eastern Frontier of Mycology. India: Elsevier; 2014.
- Jain V, Nare T, Vishwakarma K, Kundu A, Radhakrishnan A, Tak V, et al. P049 Candidemia: Isolate profiling and antifungal susceptibility testing experience from Jodhpur, Western India. *Med Mycol*. 2022;60(1):myac072P049. doi:10.1093/mmy/myac072.P049.
- Behera C, Mishra R, Jena PK, Mishra S, Sahoo B, Patnaik SB, et al. Candidemia in the pediatric intensive care unit in Eastern India. *J Pediatr Crit Care*. 2020;7(5):237–42.
- Giri S, Kindo AJ, Kalyani J. Candidemia in intensive care unit patients: A one year study from a tertiary care center in South India. *J Postgrad Med*. 2013;59(3):190–5.


14. Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: Epidemiology, prevention and management. *Mycoses*. 2018;61(9):614–22.
15. Blyth CC, Chen SC, Slavin MA. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. *Pediatrics*. 2009;123(5):1360–8.
16. Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P, et al. Emergence of non-albicans *Candida* species and antifungal resistance in a tertiary care hospital. *Jpn J Infect Dis*. 2005;58(6):344–8.
17. Rodrigues CF, Rodrigues ME, Henriques M, Candida. Infections in Patients with Diabetes Mellitus. *J Clin Med*. 2019;8(1):76.
18. Girmenia C, Martino P, De Bernardis F, Gentile G, Bocconera M, Monaco M, et al. Rising incidence of *Candida parapsilosis* fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. *Clin Infect Dis*. 1996;23(3):506–14.
19. Guinea J. Global trends in the distribution of *Candida* species causing candidemia. *Clin Microbiol Infect*. 1920;20(6):5–10.
20. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. *Nat Rev Dis Primers*. 2018;4:18026. doi:10.1038/nrdp.2018.26.
21. Seyoum E, Bitew A, Mihret A. Distribution of *Candida albicans* and non-albicans *Candida* species isolated in different clinical samples and their in vitro antifungal susceptibility profile in Ethiopia. *BMC Infect Dis*. 2020;20(1):231. doi:10.1186/s12879-020-4883-5.
22. Bhattacharjee P. Epidemiology and antifungal susceptibility of *Candida* species in a tertiary care hospital. *Curr Med Mycol*. 2016;2(2):20–7.
23. Bilal H, Hou B, Shafiq M, Chen X, Shahid MA, Zeng Y, et al. Antifungal susceptibility pattern of *Candida* isolated from cutaneous candidiasis patients in eastern Guangdong region: A retrospective study of the past 10 years. *Front Microbiol*. 2022;13:981181. doi:10.3389/fmicb.2022.981181.
24. Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. *Clin Microbiol Infect*. 2006;12(1):75–80.
25. Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and Mechanisms of Antifungal Resistance. *Antibiotics (Basel)*. 2009;9(6):312. doi:10.3390/antibiotics9060312.
26. Snyder GM, Wright SB. The Epidemiology and Prevention of *Candida auris*. *Curr Infect Dis Rep*. 2019;21(6):19. doi:10.1007/s11908-019-0675-8.
27. Arastehfar A, Yazdanpanah S, Bakhtiari M, Fang W, Pan W, Mahmoudi S, et al. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018) Get access Arrow. *Med Mycol*. 2016;59(5):422–30.
28. Sridharan S, Gopalakrishnan R, Nambi PS, Kumar S, Sethuraman N, Ramasubramanian V, et al. Clinical Profile of Non-neutropenic Patients with Invasive Candidiasis: A Retrospective Study in a Tertiary Care Center. *Indian J Crit Care Med*. 2021;25(3):267–72.

Author biography


Devashree Kshirsagar, Final Year Post Graduate  <https://orcid.org/0009-0006-4294-7712>

Vrushali Harsh Thakar, Associate Professor  <https://orcid.org/0000-0002-8206-8580>

Bharati Avinash Dalal, Associate Professor  <https://orcid.org/0000-0003-0111-8310>

Aishwarya Babu, Assistant Professor  <https://orcid.org/0000-0001-6667-8074>

Meera Modak, Professor  <https://orcid.org/0000-0003-1547-4498>

Mahadevan Kumar, Professor  <https://orcid.org/0000-0003-1656-1649>

Cite this article: Kshirsagar D, Thakar VH, Dalal BA, Babu A, Modak M, Kumar M. Candidemia in a tertiary care hospital: Changing trends. *IP Int J Med Microbiol Trop Dis* 2024;10(3):230-235.